These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2571732)

  • 1. Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
    McQuaid LA; Latz JE; Clemens JA; Fuller RW; Wong DT; Mason NR
    J Med Chem; 1989 Oct; 32(10):2388-96. PubMed ID: 2571732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic azaergoline analogues: synthesis, structural modifications, and pharmacological studies.
    Gmeiner P; Sommer J; Höfner G; Mierau J
    Arch Pharm (Weinheim); 1992 Oct; 325(10):649-55. PubMed ID: 1361322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.
    Flückiger E; Briner U; Bürki HR; Marbach P; Wagner HR; Doepfner W
    Experientia; 1979 Dec; 35(12):1677-8. PubMed ID: 520501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bi- and tricyclic ergoline analogs with dopaminergic actions].
    Gmeiner P
    Pharm Unserer Zeit; 1994 Jun; 23(3):169-73. PubMed ID: 7913751
    [No Abstract]   [Full Text] [Related]  

  • 5. Biphasic influence of a 8 alpha-amino ergoline, CU 32-085, on striatal dopamine synthesis and turnover in vivo in the rat.
    Enz A
    Life Sci; 1981 Nov; 29(21):2227-34. PubMed ID: 6119592
    [No Abstract]   [Full Text] [Related]  

  • 6. Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists.
    Bach NJ; Kornfeld EC; Jones ND; Chaney MO; Dorman DE; Paschal JW; Clemens JA; Smalstig EB
    J Med Chem; 1980 May; 23(5):481-91. PubMed ID: 7189782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-Nitroindazole enhances amphetamine-evoked dopamine release in rat striatum. an in vivo microdialysis and voltammetric study.
    Nowak P; Brus R; Oświecimska J; Sokoła A; Kostrzewa RM
    J Physiol Pharmacol; 2002 Jun; 53(2):251-63. PubMed ID: 12120900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity.
    Ohno S; Adachi Y; Koumori M; Mizukoshi K; Nagasaka M; Ichihara K; Kato E
    Chem Pharm Bull (Tokyo); 1994 Jul; 42(7):1463-73. PubMed ID: 7923470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat.
    Pifl C; Pichler L; Kobinger W; Hornykiewicz O
    Eur J Pharmacol; 1988 Aug; 153(1):33-44. PubMed ID: 2463928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum.
    Nissbrandt H; Sundström E; Jonsson G; Hjorth S; Carlsson A
    J Neurochem; 1989 Apr; 52(4):1170-82. PubMed ID: 2564423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
    Loeffler DA; LeWitt PA; Juneau PL; Camp DM; Arnold LA; Hyland K
    Brain Res Bull; 1998 Dec; 47(6):663-7. PubMed ID: 10078623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
    Booher RN; Kornfeld EC; Smalstig EB; Clemens JA
    J Med Chem; 1987 Mar; 30(3):580-3. PubMed ID: 3102743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
    Gust CM; Hemrick-Luecke SK; Fuller RW
    J Neural Transm; 1989; 75(1):11-20. PubMed ID: 2563751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive ergoline derivatives.
    Mantegani S; Temperilli A; Traquandi G; Salvati P; Di Salle E; Lamberti E; Bonsignori A
    Drug Des Deliv; 1987 May; 1(4):313-23. PubMed ID: 3509340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of dihydroergotoxine's effect on prolactin release.
    Hofmann M; Tonon GC; Spano PF; Trabucchi M
    J Pharm Pharmacol; 1979 Jan; 31(1):42-4. PubMed ID: 32366
    [No Abstract]   [Full Text] [Related]  

  • 16. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopamine metabolites in brain.
    Fuller RW; Snoddy HD
    Life Sci; 1983 Dec; 33(23):2357-61. PubMed ID: 6645804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opiate actions on mesocortical dopamine metabolism in the rat.
    Kim HS; Iyengar S; Wood PL
    Life Sci; 1986 Nov; 39(21):2033-6. PubMed ID: 3784768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of new (5R,8S,10R)-ergoline derivatives with antihypertensive or dopaminergic activity.
    Ohno S; Koumori M; Adachi Y; Mizukoshi K; Nagasaka M; Ichihara K
    Chem Pharm Bull (Tokyo); 1994 Oct; 42(10):2042-8. PubMed ID: 7805128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions.
    Ajima A; Yamaguchi T; Kato T
    Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of prolactin on the dopaminergic receptor sensitivity in striatal and limbic areas after experimentally-induced alterations in its peripheral levels.
    Cebeira M; Hernandez ML; Rodriguez de Fonseca F; de Miguel R; Fernandez-Ruiz JJ; Ramos JA
    Life Sci; 1991; 48(6):531-41. PubMed ID: 1671524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.